Advertisement

Japanese Journal of Ophthalmology

, Volume 57, Issue 1, pp 63–67 | Cite as

Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length

  • Andrea Cacciamani
  • Francesco Oddone
  • Mariacristina Parravano
  • Fabio ScarinciEmail author
  • Marta Di Nicola
  • Giorgio Lofoco
Clinical Investigation

Abstract

Purpose

To evaluate the immediate and short-term effects of intravitreal injection of 1.25 mg/0.05 ml of bevacizumab on intraocular pressure related to different ocular axial lengths.

Design

A prospective case series of consecutive patients referred to the Department of Ophthalmology, San Pietro-Fatebenefratelli Hospital, from September 2011 through January 2011.

Methods

Twenty-five patients (10 men and 15 women, mean age 70.2 ± 8.98 years) scheduled for intravitreal injection of bevacizumab for the treatment of neovascular age-related macular degeneration were enrolled in this study. Axial length was measured preoperatively using IOLMaster. Intraocular pressure was measured before injection, after 1 min and after 15 min using Tono-Pen XL tonometry.

Results

The mean intraocular pressure change following the intravitreal bevacizumab injection was 21.92 ± 6.95 mmHg after 1 min and 6.24 ± 3.77 mmHg after 15 min. The mean axial length of the examined eyes was 23.2 ± 1.06 mm. A good correlation was observed between the axial length and intraocular pressure rise after both 1 (R 2 = 0.752, p < 0.001) and 15 min (R 2 = 0.559, p < 0.001).

Conclusions

Patients undergoing intravitreal injection of 0.05 ml of bevacizumab can be exposed to intraocular pressure increases correlated to ocular axial length.

Keywords

Intraocular drugs Intraocular pressure Intravitreal injection 

Notes

Ethical standard

The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the local Ethics Committee. Each patient signed an informed consent before enrollment.

References

  1. 1.
    Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–9.PubMedGoogle Scholar
  2. 2.
    Rl Avery, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–72.CrossRefGoogle Scholar
  3. 3.
    Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularisation in pathologic myopia. Retina. 2006;26:1093–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007;85:777–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Frenkel REP, Mani L, Toler AR, Frenkel MPC. Intraocular pressure effects of Pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143:1034–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009;23:181–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Wu H, Chen TC. The effects of intravitreal ophthalmic medications on intraocular pressure. Semin Ophthalmol. 2009;24:100–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27:1044–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42:807–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Utman SA, Dhillon B. Comment on: changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2008;28:667.PubMedCrossRefGoogle Scholar
  12. 12.
    Tsui YP, Chiang CC, Tsai YY. Paracentesis before intravitreal injection of bevacizumab. Can J Ophthalmol. 2008;43:239.PubMedCrossRefGoogle Scholar
  13. 13.
    Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arc Ophthalmol. 2010;128:1523–7.Google Scholar
  14. 14.
    Kim KS, Jee D. Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique. Jpn J Ophthalmol. 2011;55:632–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Ueda T, Nawa Y, Hara Y. Relationship between the retinal thickness of the macula and the difference in axial length. Graefes Arch Clin Exp Ophthalmol. 2006;244:498–501.PubMedCrossRefGoogle Scholar
  16. 16.
    Kojima T, Tamaoki A, Yoshida N, Kaga T, Suto C, Ichikawa K. Evaluation of axial length measurement of the eye using partial coherence interferometry and ultrasound in cases of macular disease. Ophthalmology. 2010;117:1750–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Guidelines for performing intravitreal therapy. The Royal Australian and New Zealand College of Ophthalmologists. 2006.Google Scholar
  18. 18.
    Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusin P. Short-term effect of intravitreal injection of ranibizumab (lucentis) on intraocular pressure. J Glaucoma. 2009;18:658–61.PubMedCrossRefGoogle Scholar
  19. 19.
    Boon CJF, Crama N, Klevering BJ, van Kuijk FJ, Hoyng CB. Reflux after intravitreal injection of bevacizumab. Ophthalmology. 2008;115:1270.PubMedCrossRefGoogle Scholar
  20. 20.
    Pallikaris IG, Kymionis GD, Ginis HS, Kounis GA, Tsilimbaris MK. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci. 2005;45:409–14.CrossRefGoogle Scholar
  21. 21.
    Pallikaris IG, Kymionis GD, Ginis SH, Kounis GA, Christodoulakis E, Tsilimbaris MK. Ocular rigidity in patients with age related macular degeneration. Am J Ophthalmol. 2006;141:611–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol. 2011;89:138–42.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2012

Authors and Affiliations

  • Andrea Cacciamani
    • 1
  • Francesco Oddone
    • 1
  • Mariacristina Parravano
    • 1
  • Fabio Scarinci
    • 1
    Email author
  • Marta Di Nicola
    • 2
  • Giorgio Lofoco
    • 3
  1. 1.Fondazione G.B. Bietti-IRCCSRomeItaly
  2. 2.Department of Biomedical Science, Laboratory of BiostatisticsUniversity of Chieti “G. d’Annunzio”Chieti-PescaraItaly
  3. 3.Ospedale Fatebenefratelli San PietroRomeItaly

Personalised recommendations